Trial Profile

Kisqali Access Registry for Metastatic Breast Cancer in Australia

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Aromatase inhibitors
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms KARMA

Most Recent Events

08 Jun 2021 Results (n=610) assessing real world outcomes and compared with trial MONALEESA-2 ribociclib/letrozole cohort (n=334) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
14 Dec 2019 Trial design of a clinical trial describing the real world clinical and tumor characteristics of patients with HR+ HER2 negative metastatic Breast Cancer in Australia who have received ribociclib in combination with an AI as part of the ribociclib MAP and/or SPARK access program, and treatment details of AI plus ribociclib, released at 42nd Annual San Antonio Breast Cancer Symposium.
19 Aug 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com